PCOS and Fertility: Complete Guide to Getting Pregnant With PCOS

PCOS and Fertility: The Complete Evidence-Based Guide

PCOS (Polycystic Ovary Syndrome) is the most common cause of anovulatory infertility, affecting 6–12% of women of reproductive age worldwide. Despite this, most women with PCOS can achieve pregnancy — either naturally or with treatment. The key is understanding how PCOS affects fertility and which interventions have the strongest evidence.

How PCOS Causes Infertility

PCOS disrupts fertility primarily through irregular or absent ovulation, driven by this chain:

1. Insulin resistance → elevated insulin levels
2. Elevated insulin stimulates the ovaries to produce excess androgens (testosterone, androstenedione)
3. Excess androgens disrupt normal follicle development, preventing the dominant follicle from releasing an egg
4. The result: multiple small arrested follicles (the "polycystic" appearance on ultrasound) but no ovulation

Additional mechanisms: elevated LH:FSH ratio, altered endometrial receptivity, and increased miscarriage risk from the abnormal hormonal environment.

PCOS Diagnosis: Rotterdam 2023 Criteria

Diagnosed when 2 of 3 criteria are met, after excluding other causes:

AMH in PCOS: The 2023 International Evidence-Based Guideline (ASRM/ESHRE/NHMRC) endorses AMH ≥3.5 ng/mL as a replacement for polycystic morphology on ultrasound for women aged 20–39, using high-quality AMH assays — simplifying diagnosis and avoiding transvaginal ultrasound in some cases.

Your Chances of Conceiving With PCOS

Natural conception: Women with PCOS who ovulate occasionally can conceive naturally. Those with less severe PCOS (regular-ish cycles, normal male partner) have reasonable natural rates — but time to pregnancy is typically longer.

With letrozole treatment (per 2023 International Guideline):

• Live birth rate: 27–32% per cycle
• Cumulative live birth rate: 60–70% after 6 cycles

IVF in PCOS: Live birth rates are typically equal to or better than non-PCOS patients of the same age, due to higher egg numbers. The main IVF concern is OHSS risk.

Evidence-Based Treatment Hierarchy

The 2023 International Evidence-Based Guideline for PCOS (ASRM/ESHRE/NHMRC) — the highest-quality PCOS guideline in existence — defines the following hierarchy:

First-Line: Lifestyle Modification (for overweight women)

For overweight or obese women with PCOS, lifestyle modification is first-line before any medication:

• 5% weight reduction restores ovulation in 55–60% of anovulatory PCOS women
• Mechanism: weight loss reduces insulin → reduces androgen → restores ovulation
• Low GI diet + HIIT exercise is the most effective combination
• The 2023 guideline recommends lifestyle modification as primary treatment, with medication added if needed

First-Line Medication: Letrozole (Grade A — strongest evidence)

The 2023 International Guideline definitively recommends letrozole as first-line pharmacological ovulation induction for anovulatory PCOS, replacing clomiphene. The pivotal NEJM RCT (Legro et al, 2014) showed letrozole achieved significantly higher live birth rates (27.5% vs 19.1% per cycle) with lower twin rates.

How it works: letrozole inhibits estrogen synthesis → removes negative feedback on pituitary → more FSH released → follicle development. Dose: 2.5–7.5mg, Days 3–7, with ultrasound monitoring.

Adjunct: Metformin (Grade B)

Metformin (insulin sensitiser) combined with letrozole significantly improves ovulation rates in insulin-resistant/obese PCOS women. Also reduces OHSS risk in IVF and miscarriage in early pregnancy. Standard dose: 1500–2000mg daily (start low at 500mg, titrate over 4 weeks to reduce GI side effects).

Second-Line: Clomiphene Citrate (for letrozole non-availability only)

Per 2023 guideline: acceptable if letrozole is unavailable, but inferior in PCOS — lower live birth rate, higher multiple pregnancy risk, anti-estrogenic endometrial effects.

Second-Line: Gonadotropins (FSH injections)

For letrozole non-responders. Low-dose protocol (37.5–75 IU FSH, step-up) with mandatory monitoring to prevent multiple follicle development and OHSS. Requires specialist monitoring every 2–3 days.

Second-Line: Laparoscopic Ovarian Drilling (LOD)

Surgical punctures in each ovary using electrosurgery/laser. Destroys androgen-producing stromal tissue → normalises LH:FSH ratio → restores ovulation. Appropriate for women who have not responded to oral agents where laparoscopy is already planned.

Third-Line: IVF

Recommended after failed oral ovulation induction for 6 cycles, or when additional factors are present (tubal, severe male factor).

PCOS-specific IVF protocol (ASRM/ESHRE OHSS Prevention 2023):

• GnRH antagonist protocol (not long protocol) — reduces OHSS by 50%
• Low starting FSH dose (100–150 IU)
• GnRH agonist trigger (not hCG) — eliminates late-onset OHSS
• Freeze-all strategy — no fresh transfer; FET in a later cycle
• Metformin during stimulation — further reduces OHSS risk

With these protocols, IVF in PCOS achieves excellent outcomes with dramatically reduced OHSS risk.

Myo-Inositol: The Evidence-Based PCOS Supplement

The 2023 International Guideline endorses myo-inositol as an adjunct. Evidence:

• Restores ovulation in 50–65% of anovulatory PCOS women within 3 months
• Reduces testosterone and LH
• Improves insulin sensitivity (similar mechanism to metformin, fewer GI side effects)
• Improves egg quality in IVF

Standard dose: 4g myo-inositol + 400mg D-chiro-inositol (40:1 ratio) daily. Safe to continue during fertility treatment and early pregnancy.

PCOS Pregnancy Risks

Women with PCOS who conceive have elevated risks requiring appropriate monitoring:

• Gestational diabetes: 2–3× baseline → screen at 24–28 weeks (ACOG 2022)
• Hypertensive disorders (pre-eclampsia): 2–3× elevated
• Miscarriage: ~20–30% vs ~15% without PCOS — metformin in early pregnancy reduces this risk per 2023 guideline
• Preterm birth: modestly elevated

These risks require appropriate antenatal monitoring but do not contraindicate pregnancy.

Reference: Teede HJ et al — 2023 International Evidence-Based Guideline for PCOS (ASRM/ESHRE/NHMRC). Legro RS et al — Letrozole vs Clomiphene for PCOS, NEJM 2014. ACOG Practice Bulletin No. 194 — Polycystic Ovary Syndrome, 2018 (reaffirmed 2023). ESHRE Guideline — Anovulatory Infertility, 2023.